Abstract-The past three decades have seen numerous advances in tissue engineering and regenerative medicine (TERM) therapies. However, despite the successes there is still much to be done before TERM therapies become commonplace in clinic. One of the main obstacles is the lack of knowledge regarding complex tissue engineering processes. Imaging strategies, in conjunction with exogenous contrast agents, can aid in this endeavor by assessing in vivo therapeutic progress. The ability to uncover real-time treatment progress will help shed light on the complex tissue engineering processes and lead to development of improved, adaptive treatments. More importantly, the utilized exogenous contrast agents can double as therapeutic agents. Proper use of these Monitoring/ Imaging and Regenerative Agents (MIRAs) can help increase TERM therapy successes and allow for clinical translation. While other fields have exploited similar particles for combining diagnostics and therapy, MIRA research is still in its beginning stages with much of the current research being focused on imaging or therapeutic applications, separately. Advancing MIRA research will have numerous impacts on achieving clinical translations of TERM therapies. Therefore, it is our goal to highlight current MIRA progress and suggest future research that can lead to effective TERM treatments.
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INTRODUCTION
Tissue engineering and regenerative medicine (TERM) have been actively researched for over three decades. 18 TERM research's goal is to develop therapies that replace diseased or damaged tissue with healthy, functioning tissues. Treatments are often multifaceted and may include cells, biomolecules, biomaterials, and imaging aspects. Although TERM research has seen numerous advances in recent years these have been primarily for skin, cartilage, and other simple connective tissues. As a whole, the field has not yet lived up to its expectations in clinic. 179 Regeneration of more complex organs has proven problematic partly because the healing and remodeling process remains poorly understood. In order to advance treatment success, knowledge about therapeutic progress along with material and tissue changes must be uncovered in real-time. Traditionally, information on TERM treatments came from end point analysis, such as histology or tissue function restoration. Real-time, non-invasive monitoring of treatment progress may allow TERM treatments to realize their full potential. In order to achieve this level of characterization, imaging strategies must be implemented. Imaging techniques have already helped with monitoring TERM therapies and recent progress is discussed elsewhere. 5, 127 To gain more detail and functional information, introduction of exogenous contrast agents is essential. These agents can be used to track stem cells (SCs), assess scaffold integrity, and convey functional changes. Furthermore, many of these agents have the added benefit of providing therapy.
Combining their therapeutic and imaging capabilities can enhance therapeutic outcomes and also allow realtime, continuous monitoring of treatments. Particles that double as Monitoring/Imaging and Regenerative Agents (MIRAs) may provide the necessary knowledge to achieve successful TERM therapies and their translation to clinic.
The use of MIRAs is still in its emerging stages. While a similar idea using multifunctional particles has been extensively explored for cancer applications, dubbed theranostic (therapy and diagnostic) agents, 192 the TERM field has not widely explored the dual role of MIRAs. Instead, much of the research remains independent, focusing on either the therapeutic or imaging/monitoring benefit. Recently, focus has shifted to studying synergistic capabilities of MIRAs, but their full potential remains to be discovered.
Our goal is to review the current stages of particlebased MIRAs and suggest future opportunities for investigation. Because the final goal of treatment is clinical utility, we will concentrate on clinically practical MIRAs and imaging modalities. Therefore, we will emphasize photoacoustic (PA), ultrasound (US), magnetic resonance imaging (MRI), X-ray, and nuclear imaging modalities, such as positron emission tomography (PET), and describe the use of silica, gold, iron oxide, carbon, and perfluorocarbon particles (PFCps) as MIRAs (Table 1) . Although other MIRA possibilities, such as quantum dots and reporter-gene imaging agents demonstrate preclinical utility, they fall out of scope of this review as our focus is on particulate materials capable of deep imaging. Therefore, these are not included because quantum dots are restricted to optical detection techniques with shallow imaging depths, and reporter genes are molecular, not material-based MIRAs.
GOLD NANOPARTICLES
Colloidal gold has been used for centuries in medical and aesthetic applications. Initially, colloidal gold was of interest for its red color, for example in the famous color-changing Lycurgus Cup and stained glass windows. Since then, the development of Mie theory in the early 1900s explained that the color relates to the surface plasmon band. Mie theory continues to provide theoretical framework to describe the optical properties of these nanoparticles. 38 Today, gold nanoparticles (AuNPs) continue to be widely explored for biomedical applications and are excellent MIRAs due to their stability, biocompatibility, ease of synthesis and functionalization, and tunable optical properties. 38, 147, 192 AuNPs can be synthesized in a variety of sizes and shapes, including cages, rods, and 45, 190 High: PFCs are inert and are rapidly cleared 150, 190 US, MRI, PA imaging Drug, gene or gas delivery
Short lifetimes, large size of micro particles spheres. 148, 158 Varying geometry allows fine-tuning of optical properties due to gold's plasmonic nature. This property, known as surface plasmon resonance (SPR), creates a unique optical signature specific to particle composition. 38, 192 The SPR and high optical absorption make AuNPs attractive contrast agents for PA imaging. 32, 83, 126, 204 In X-ray/computed tomography (CT), AuNPs are investigated as alternatives to gadolinium, barium, or iodine-based agents due to their longer circulation time and improved contrast. 62, 75 AuNP synthesis differs according to shape and size. Citrate reduction is a popular technique for making spheres, where varying the ratio of citrate to gold correlates with particle size. 38, 192 Figure 1a from Nam et al. shows an example of a TEM image of 20 nm AuNPs. 126 Synthesis of other shapes require capping agents, for example cetyltrimethylammonium bromide (CTAB) in nanorod synthesis. 192 Though nanorods are favored for PA imaging, CTAB is highly toxic, and additional protective layers and careful purification is required, especially for TERM applications. 1 For functionalization, thiolated biomolecules easily bind to the particle surface. 192 
AuNPs as MIRAs
Since AuNPs are cytocompatible, do not negatively impact cell differentiation, and are easily taken up by cells via receptor-mediated endocytosis, they are of great interest for cell tracking applications. 30, 147 While AuNPs can be used with optical imaging modalities to track SCs, we emphasize their use with X-ray/CT and PA/US due to greater imaging depth and clinical translatability. In vivo experiments using CT can provide migratory information. For example, AuNP-labeled mesenchymal stem cells (MSCs) could be followed as they migrated to a brain tumor. 116 Gold nanocages (AuNCs), gold nanorods (AuNRs), and gold nanospheres (AuNSs) generate strong PA signals to track cell location and migration. 83, 126, 204 Although AuNSs typically absorb around 520 nm where penetration depth is limited, SPR coupling upon MSC endocytosis generates a strong PA signal and a sensing mechanism to know particles are within cells (Fig. 1b from Nam et al.) . 126 Though this is useful for cell tracking, it is disadvantageous for imaging other TERM therapies, such as scaffold remodeling where AuNSs are too far apart to generate substantial signals. While AuNRs or AuNCs may be more favorable for TERM imaging, they are more difficult to synthesize, are less stable than spheres, and rods are toxic without rigorous purification or further coating. 1, 29, 158 Though tracking cell location is useful for therapeutic optimization, collecting functional information, including proliferation, neovascularization, and immune response, is critical to future development of TERM therapies. Experiments using X-ray/CT show great sensitivity to cellular events. In vitro experiments using nano/microCT could follow individual cells and mitosis by detecting AuNP distribution between daughter cells. 7 CT can also evaluate tumor growth rate and cell doubling time from the AuNP loading concentration and changes in the X-ray attenuation coefficient. 8 These measures of proliferation could apply to SC divisions, survival, and therapy success. Although neovascularization can be detected through PA imaging of hemoglobin absorbance, it is difficult to detect and distinguish new vessels. Integrin-targeted gold nanobeacons (GNBs) were developed to target only nascent vasculature and generated strong, specific PA signals in vivo. 135 To assess immune response, interactions between macrophages and MSCs can be observed during wound healing with a dual labeling system. In one recent study, AuNR-labeled MSCs were implanted in vivo along with free PEGylated AuNSs. As macrophages infiltrated the area and endocytosed the spheres, macrophage signal increased and was distinct from the MSC signal, providing a time course between cellular traffic and wound healing events. 148 Given the complex cellular interactions in the wound healing environment, future development of multi-labeling systems could provide valuable insights for improved MIRAs and TERM therapies.
In many of the previous examples, AuNPs were passively delivered to cells, but the surface can be easily functionalized for targeting, multimodal imaging, and biomolecule, drug, or gene delivery. Cytokine coatings have shown beneficial effects on modulating inflammation, while vascular endothelial growth factor receptor (VEGFR), antioxidants, or heparin manipulate wound healing and angiogenesis. 13, 50, 87, 103 The advantage of delivering biomolecules with AuNPs vs. biomolecules alone is enhanced delivery. 103 Other cell alterations can be induced using AuNPs for gene and drug delivery. Cages are especially well suited for this application. AuNCs covered with smart polymers or phase-changing materials can encapsulate drugs or genetic material. Upon an external trigger, such as temperature change, these materials shrink and release the payload. 120 Other recent studies deliver genetic material through surface coatings. For example, AuNRs linked with siRNA could cross the bloodbrain barrier (BBB) and knockdown dopaminergic signaling. 20 This provides an excellent platform for treating neurodegenerative disorders. Several studies have also induced osteogenesis and neurogenesis in SCs using plasmid DNA (pDNA) sequences linked to AuNPs. 95, 125 Based on the contrast capabilities of AuNPs, in the future many of these delivery systems can be combined with cell tracking immediately in proof-of-concept studies.
Beyond surface modifications, AuNPs inherently possess qualities to manipulate angiogenesis or differentiation. 92, 124, 198 When MSCs were incubated with osteogenic differentiation media and AuNPs, higher concentrations of AuNPs increased osteogenic and reduced adipogenic differentiation through mechanotransduction. Figure 1c from Yi et al. depicts the impact of AuNPs on alkaline phosphatase (ALP) expression. 198 Gold's ability to manipulate cellular response adds to its utility as a MIRA since AuNPs can impact parallel signaling pathways without additional surface modifications. This creates more potent TERM treatments while limiting unwanted side effects. However, the osteogenic and antiangiogenic qualities of AuNPs could be harmful in certain situations, such as cardiovascular applications. This problem could be mitigated through appropriate functionalization, but more research is needed as their role as MIRAs develops.
The influence of AuNPs on mechanical signaling is further utilized in scaffolding. AuNPs can add patterning, electrical stimulation, or points for cell-matrix interactions. A silk + AuNP scaffold was developed to increase scaffold stiffness, introduce 3D nanotopography, and add adhesion sites. When seeded with MSCs, cell spreading and density increased compared to smooth scaffolds. 35 Another study demonstrated gold-coated collagen nanofibers improved mechanical stability of the scaffold. 131 Gold, conductive scaffolds can induce MSCs towards neural and cardiac lineages. 131 For cardiovascular engineering, electrical stimulation drastically improved tissue function, seen through increased connexin-43 expression, more contractions/minute, lower excitation thresholds, and/or better conductivity between cells. 46, 131, 201 Figure 1d from You et al. provides an example of improved cardiomyocyte response in scaffolds with AuNPs and electrical stimulation. 201 While some AuNP delivery systems could immediately expand to cell tracking, scaffold monitoring is more of a challenge. Though PA imaging can be used to evaluate changes in oxygen saturation and vasculature at the scaffold site, higher resolution is needed to observe deeper changes in scaffold structure in vivo. 23 
Current Limitations
Before AuNPs can be further developed as MIRAs problems such as particle cost, clearance, and degra-dation need to be addressed. AuNPs are cytocompatible in short-term studies, but there are concerns regarding long-term toxicity since the particles do not degrade. This issue can be avoided using AuNPs less than 5 nm diameter to allow renal clearance, but in this size range the PA signal is weak and circulation time is extremely short, limiting utility as a contrast agent. 31 An alternative approach is biodegradable nanoclusters, composed of AuNSs small enough for clearance. 200 However, controlling the degradation process of nanoclusters poses another challenge. Besides toxicity, limitations on large particle degradation and clearance brings up contrast transfer issues, also common to other MIRAs. When a labeled cell dies and is cleared by macrophages, the AuNPs are also transferred to the macrophage. As a result, the macrophage mistakenly appears as a cell of interest, reducing the specificity of the signal. Though the dual labeling system described previously is a step in the right direction, further research is needed. 148 Until issues of long-term toxicity, clearance, and degradation are solved, clinical translation of AuNPs as MIRAs is hindered.
Outlook
AuNPs have been widely used for TERM monitoring and therapy separately. Though their combined use is minimally explored, the current state of research shows foundations exist for their use as effective MIRAs. The inertness of Au and high AuNP cell uptake makes them adept cell trackers, ease of surface modification allows a range of therapeutic applications, and electrical properties add a unique role as scaffold enhancers. Many of the described systems have all the components for immediate testing in proof-of-concept experiments combining TERM therapy and imaging, particularly for simultaneous delivery and cell tracking applications. Compared to the other MIRAs reviewed, AuNPs are best suited for applications related to cell tracking with PA imaging. Though AuNPs provide strong Xray/CT contrast and could have a unique role in delivering therapeutics while assessing bone regeneration, it seems there is much room for research using AuNPs for PA imaging. The structure of AuNPs offers a wide range of opportunities for tracking multiple cellular events, and this is not as straightforward for other MIRAs. Furthermore, the ease of combining AuNPs with siRNA, biomolecules, or drugs, is a clear route to simultaneous TERM therapy and monitoring. Overall, the future of gold MIRAs is bright, and solutions to better link monitoring and therapy may include multimodal imaging and designing gold MIRAs as nanosensors.
IRON OXIDE NANOPARTICLES
Iron oxide nanoparticles (IONPs), also known as superparamagnetic iron oxide nanoparticles (SPIONs), are unique MIRAs due to their inherent magnetic properties. They respond to external magnetic field gradients, and upon removal there is no remnant magnetization. This is an important attribute that reduces risk of aggregation. 60, 185 Imaging and delivery applications take advantage of IONPs' magnetic properties, while their biocompatibility and ease of controlling mobility make them attractive for a variety of TERM uses. 187 The use of IONPs as MRI contrast agents was first reported almost four decades ago using dextran-coated magnetite particles with sizes from 5 to 20 nm in gel systems. 128 At the same time, the particles were being studied to enhance delivery of chemotherapeutic agents using external magnetic fields. 189 It was soon suggested that MRI could be used to follow in vivo distribution of these agents. 130 Since then, they have been widely used to reduce local T 2 /T 2 * relaxation time and yield negative contrast in T 2 -weighted images. Although capable of reducing T 1 relaxation time, the effect is not as significant as that on T 2 /T 2 * due to a high T 2 /T 1 relaxivity ratio. 85, 185 Current IONP research has evolved to include therapeutic delivery roles, cell labeling, and magnetic hydrogels, highlighting their MIRA capabilities.
IONPs are commonly synthesized through chemical co-precipitation of iron oxides. Typically used iron oxides are maghemite (c-Fe 2 O 3 ) and magnetite (Fe 3 O 4 ), which are biocompatible and approved for clinical use. 51, 184, 187 To synthesize, Fe 2+ and Fe 3+ ions are co-precipitated in an aqueous salt solution by addition of a base. Varying type of salts, ion ratio, and pH dictates geometry. 60, 99, 113 More information on coprecipitation and synthesis methods can be found in other sources. 60, 73, 99, 113 Beyond basic synthesis techniques, surface modifications impact kinetics, reduce toxicity, prevent aggregation, and enable functionalization for therapeutic use. This is usually achieved with a hydrophilic polymer surface coating, such as polyethylene glycol (PEG), polyvinyl alcohol (PVA), poly(acrylic acid), poly(lactide-co-glycolide) (PLGA), poly(ethyleneimine) (PEI), or various polysaccharides like dextran, chitosan, and pullulan. 10, 60, 109, 113, 184 
IONPs as MIRAs
Numerous studies have used IONPs in conjunction with MRI to monitor cell distribution in vivo. For MSC tracking, IONPs are bound to the cell membrane or taken up by cells through different surface modifications. 10, 164, 166 Studies show MSC labeling does not negatively affect cell viability 51 or ability to differentiate, regenerate tissue, and self-renew. 11, 104, 163 IONPs can also be used to transport SCs and other therapeutic agents. Their transport and location has been monitored in the brain, 26 heart, 68 vasculature, 149 muscle, 3, 167 and joints. 80 IONPs enhance accumulation of cells to a specific site when a static magnetic field is applied by placing external or implanted permanent magnets. 26, 149 This effect can be confirmed with MRI (Fig. 2a from Talaie et al.) . 167 Further studies of external magnet effects on therapeutic agent kinetics would help optimize and control their placement depending on monitored therapy outcome.
IONPs have also been used to deliver genetic material. Additional coatings like PEG, 137 lipid-like materials, 77 PEI, and chitosan, 90 allow pDNA loading onto a cluster of particles (Fig. 2b from Jiang et al.) . Mesoporous IONPs provide increased carrier loading by utilizing both inner and outer cavities. 25 Loaded IONPs can then be incubated with cells prior to implantation, or delivered via an external magnetic field that guides clusters to the desired site. For example, one study used polypeptide-coated, fluorescently labeled IONPs to show in vivo transfection and tracking of MSCs using multimodal MR/optical imaging. 138 Magnetofection can enhance transfection by pulling the genes toward the target cells when an external magnetic field is applied. 42, 142 A magnetofection study using PEG-coated IONPs crosslinked with vascular endothelial growth factor (VEGF) pDNA showed elevated VEGF production from rat MSCs for cerebral ischemia therapy (Fig. 2c from Plank et al.) . 137 Another strategy is conjugating IONPs with ligands to enhance receptor-mediated endocytosis and increase treatment efficacy. 104 Mechanical and thermal stimulation with different magnetic field regimens FIGURE 2. (a) MRI shows in vivo accumulation and retention of IONP-containing platelets when a magnet is positioned on the left leg of the animal. 167 (b) Nucleic acids can be loaded on lipid-coated IONP for gene delivery applications. 77 (c) Magnetofection principle increases gene delivery efficiency by pulling the vectors and target cells together. 142 (d) A macroporous ferrogel is deformed when an external magnetic field is applied. (e) SEM images show a freeze-dried macroporous ferrogel in undeformed and deformed states (Scale bar 5 500 lm). 205 would be an interesting area to study as it can affect MSC fate 54, 59 and has not been thoroughly explored. Alternative IONP-based delivery mechanisms involve loading them into hydrogels and controlling release of proteins or cells. While conventional scaffolds usually depend on passive release of cells and agents, IONPs enable control via magnetic stimulation that deforms or increases hydrogel temperature (Figs. 2d and 2e from Zhao et al.). 70, 106, 118, 205 Other studies show magnetic scaffolds can reload IONP-labeled growth factors (GFs) and SCs through magnetic attraction. This technique allows for a higher degree of control during TERM therapies, compared to traditional approaches where agents must be preloaded before implantation, 19 and it could be used for longterm treatments that would otherwise be limited by the hydrogel environment. More studies on long-term outcomes are needed to elucidate the full potential of magnetic scaffolds.
IONPs are also studied as imaging agents in magneto-motive based modalities 81, 115, 129 and for combined MRI and nuclear imaging when IONPs are radiolabeled. 40, 102 Magneto-motive modalities offer cost-efficient, localized monitoring. Combining MRI with nuclear imaging adds increased sensitivity while preserving spatial resolution of MRI. Although IONPs could serve as PA imaging agents, use of this modality would not be ideal because of their low absorption in the near infrared (NIR) which implies limited imaging depth. 36 Research on combined multimodal particles can potentially improve these capabilities. 78 
Current Limitations
The fact that MRI is the most widely used modality to monitor IONP distribution means their use as MIRAs frequently shares this technology's limitations, including high cost, low sensitivity, and inability for real-time imaging. Another limitation of IONPs as MRI-based MIRAs is that their negative contrast makes detection difficult in dark, low-contrast regions. 21, 161 To combat this issue, gadolinium-labeled IONPs have been investigated as a solution to increase both T1 (positive) and T2 contrast. 9 Other studies have been able to obtain positive contrast in vivo by modifying imaging sequences or applying post-processing algorithms. 37, 206 Adding nuclear imaging could improve contrast and sensitivity limitations in a full-body image, while a technique like magneto-motive ultrasound could be used to closely examine a specific area in real-time. These additions would allow for more extensive TERM treatment monitoring.
In cell tracking studies, the loss of contrast resulting from cell division and transfer of nanoparticles to nonstem cells can lead to underestimation and overestimation, respectively. 173, 181 Both issues limit accurate, long-term monitoring of therapy efficacy. Ex vivo experiments have revealed that IONPs from dead stem-cells are phagocytosed by macrophages, an effect otherwise indistinguishable on in vivo MRI. 112, 209 Overestimation of cells could be improved with surface functionalization to reduce non-specific macrophage uptake 193 or by using additional agents to detect macrophages, similar to strategies with AuNPs. 148 
Outlook
Magnetic delivery is thus a prominent application of IONPs. The use of nuclear imaging and magnetomotive techniques can improve monitoring by adding sensitivity and versatile real-time imaging. Challenges still remain to be able to identify SC quantity over time; however, synergistic use of IONPs and other agents, like AuNPs, could help distinguish SCs from macrophages while allowing use of static fields for cell guidance. IONPs have a promising future, be it as a single agent, multi-agent, or multimodal uses. Additional in vivo studies will help elucidate their roles as effective MIRAs.
CARBON NANOTUBES
Carbon nanotubes (CNTs) are a subset of the fullerene carbon allotrope family. Although unintentionally observed around the 1960s, the official discovery of CNTs is credited to Iijima in 1991. 74 Since then, CNTs have been studied in a variety of applications including electronics, catalysts, sensors, and biomedical. 133 CNTs consist of single or multiple rolled up sheets of graphene and are called single-walled (SWCNTs) or multiple-walled (MWCNTs), respectively. 197 CNTs are characterized by long lengths and nanometer diameters leading to large aspect ratios. Their high surface area and ability to be strategically functionalized, combined with their excellent mechanical and electrical properties, have led to a wide range of CNT applications, from drug/protein carriers to scaffold enhancers. 44, 65, 145 Additionally, CNTs act as contrast agents for clinically relevant imaging modalities such as PA, US, MRI, and nuclear imaging. 39, 41, 186 CNTs can act as contrast agents for different in vitro optical imaging techniques and Raman spectroscopy, but these features are discussed in other sources. 56, 71, 108, 110 Various studies demonstrate CNT ability to serve as T2-weighted contrast agents for MRI. Their T2 contrast arises from lingering iron atoms used during the nanotube synthesis and from the carbon material itself.
2 Addition of MRI contrast agents, such as IONPs or gadolinium, enhances CNT contrast abilities. Attaching IONPs to CNTs further increases T2 contrast, 89 while adsorption of gadolinium chelates to CNTs cause a contrast increase for both T1 and T2-weighted images. 146 Bare CNTs show PA contrast when injected into mice 39 due to strong optical absorbance in the NIR region. 86 Functionalization of higher optically absorbing agents further increases contrast. For example, gold plated CNTs showed a 100 fold enhancement in signal, 91 while conjugation of indocyanine green (ICG) showed a 300 fold signal increase in in vivo studies (Fig. 3a from Zerda et al.).
203
CNTs are commonly synthesized by chemical vapor deposition involving metal catalysts. 65, 84 The metal remains on the formed nanotubes, raising concerns of cytotoxicity. However, appropriate purifying techniques, such as acid etching, remove the majority of metal atoms and simultaneously generate nanotube defects for functionalization points. 65, 192 Functionalization of CNTs is essential as it reduces their tendency to aggregate and cytotoxicity through a reduction in hydrophobicity. 188 Appropriate techniques are discussed elsewhere.
108,170,175
CNTs as MIRAs
CNTs are attractive stem cell trackers because they are readily taken up by cells, and appropriate functionalization and dose show no adverse effect on MSC viability, proliferation, and differentiation potential. 121, 182 One example of cell tracking was shown by pre-labeling MSCs with SWCNTs which allowed in vivo MRI and PA tracking. 186 As noted earlier, SC tracking is important for TERM applications to ensure implanted cells are at the desired location.
Due to high cell uptake, CNTs have also been explored to deliver TERM therapeutics. Their high surface area and design allows for immobilization of therapeutics through functional attachments, adsorption, or entrapment (Fig. 3b from Hirsch et al.) .
34,69
The remaining hydrophobic portions of the CNTs are able to interact with cell membranes for efficient uptake. 65 If desired, CNTs can be functionalized with cationic polymers, such as PEI, to improve transfection capabilities. 123 For drug delivery, compounds with aromatic groups can easily link to CNTs through p-p stacking. 180 Drugs can also bind to CNTs through amide or ester linkages to COO-groups present at CNT defect sites. 192 If specific cell targeting is required, CNTs can be functionalized with receptor-targeted ligands. 180, 186 PA/US techniques can control cargo release and monitor CNT location, highlighting their MIRA potential. In one study, in vivo US monitoring of MWCNTs was done in combination with targeted drug delivery. 191 Since CNTs absorb strongly in the NIR region, irradiation at these wavelengths can elicit changes to release cargo. 86 Other examples of controlled release include microcapsules, or spherical hydrogels, embedded with CNTs and the desired biomolecules. 139, 208 Upon irradiation, CNTs convert the absorbed light into heat, thereby increasing membrane permeability or rupturing the capsule for cargo release. While the majority of these studies looked at cancer drug delivery, TERM therapies would benefit from similar controllable in vivo therapeutic delivery and monitoring. One can envision CNTs functionalized with different absorber-therapeutic pairs that can be selectively triggered based on irradiation wavelength. This would allow for controlled release of multiple therapeutics to enhance individual or synergistic TERM therapies.
Laser irradiation of CNTs alone has also shown TERM therapeutic benefits. NIR irradiation of CNTs cultured with MSCs provoked cells to release elevated levels of calcium, ALP, and osteopontin, indicating differentiation towards osteoblasts, as shown in Fig. 3c from Green et al. 58 Similarly, irradiation of CNTs within an alginate gel induced bone growth in vivo. 195 It is postulated that bone formation results from photothermal therapy triggered by the localized heating of CNTs following irradiation.
The diversity of CNTs as MIRAs is supported by their wide array of applications within scaffold engineering. Their hexagonal carbon network gives them lightweight, superior mechanical properties and unique electrical properties. 122, 175 In bone TERM applications, incorporating CNTs into polymeric scaffolds increases mechanical strength. 117, 157 For example, addition of CNTs into PLGA scaffolds improved the compressive strength and moduli two and three times, respectively, over PLGA scaffolds alone. 117 In vivo studies of CNTbased arrays or CNT scaffold composites demonstrate good cell attachment, proliferation, osteogenic differentiation, and integration. 98, 107, 156 CNTs also possess high electrical conductivity; consequently, they have been studied for neural and cardiac TERM applications. 101, 122 Several in vitro studies have shown the ability of CNTs to direct neuronal growth and enhance signal transfer. 101, 152, 202 The success of these in vitro studies supports further exploration through in vivo studies. Integration of CNTs into scaffolds also allows for scaffold degradation and tissue ingrowth monitoring. 22 Groups have demonstrated the ability to use PA/ US to monitor blood vessel ingrowth and scaffold location ex vivo 24 and in vivo. 168 This feature could benefit from future studies as longitudinal characterization of such parameters is important for monitoring angiogenic TERM therapy progress.
Lastly, CNTs have been investigated as various types of biosensors ranging from electrochemical to optical sensors. Optical CNT sensors can monitor levels of glucose and other signaling molecules, such as nitric oxide (NO). 12, 177 NO signals vasodilation; therefore, monitoring NO levels could convey local changes of blood dynamics in response to TERM therapies. Unfortunately, the current technology of these applications relies on detecting CNT fluorescent changes upon molecule binding and therefore has limited sensing depths. 196 Studying alternative detection methods to increase depth-sensing capabilities or ways to relay information to an external monitor would be beneficial.
Current Limitations
CNTs possess many unique properties that make them attractive MIRAs, but some of these same properties raise concerns for their use in medical (5) defect-group functionalization. 69 (c) Depiction of irradiation effects in conjunction with CNTs and gold nanoparticles. CNTs incubated with MSCs and irradiated showed the biggest increase in ALP production. CNTs and gold nanoparticles adjacent to MSCs and irradiated showed more ALP production over controls without particles, but also irradiated. 58 applications. As of yet, CNTs are not FDA approved or in clinical trials. Their non-degradability leads to questions of biodistribution and persistence which remain to be properly answered. 55 As previously mentioned, functionalization of CNTs decreases cytotoxic side affects and also effects pharmacokinetics by decreasing CNT clearance time. 55 It appears CNT type, dose, and functionalization prove key in determining their biocompatibility. The TERM field would benefit from future studies to clearly identify and optimize the best form of CNTs for biomedical use to clarify discrepancies. For instance, several studies involving CNTs for tracking cells showed no cytotoxic or differentiation effects, 44, 121, 182 yet others have demonstrated CNTs negatively impact cell proliferation or differentiation. 111 
Outlook
CNTs have clearly demonstrated their ability to act as effective MIRAs. Although CNTs show contrast in US, PA, and MRI applications, they are inherently best suited for PA applications. Bare CNTs show little US and MRI contrast and often have to be functionalized with other agents (i.e. IONPs). Additionally, CNT cargo can be triggered to release via PA techniques. Another interesting area for future exploration is CNT incorporation into scaffolds. CNTs have already demonstrated the ability to increase physical and conductive properties of scaffolds while allowing non-destructive characterization and monitoring of therapy progress. There is still much to be done to benefit from CNTs as MIRAs and expedite their path to clinical use, including investigating CNT parameter influence on biocompatibility and clearance. 140 Once this has been optimized, areas such as targeted/controlled drug delivery and longitudinal scaffold and tissue in-growth assessment could gain from CNT's unique properties.
SILICA-BASED PARTICLES
Silica is a well-characterized biocompatible material with tunable parameters such as size, porosity, and surface chemistry. Silica-based nanoparticles fall into two predominant categories, mesoporous silica nanoparticles (MSNs) and solid silica nanoparticles (SiNPs) (Fig. 4a from Chen et al. and Vivero-Escot et al.). Material MCM-41 was discovered by the Mobil Corporation as a potential catalyst in 1992 and is the most commonly used in MSNs. 16 Its potential for biomedical applications was not researched until the early 2000s and has been rapidly investigated since then. Silica particles display ultrasound echogenicity, but are mostly used to incorporate a variety of imaging motifs due to their large surface area, porosity, and surface functionalization. Contrast agents are doped into silica particles for MRI, PET, and NIR fluorescence imaging. Functionalizing silica particles allows them to contain multiple contrast agents and deliver therapeutics for TERM applications. Additionally, silica-based particles have applications in scaffold engineering and cell monitoring. 27, 52, 155 The most widely used silica nanoparticle synthesis method is the Sto¨ber method developed by Sto¨ber and co-workers in the 1960s. 162 The method consists of hydrolysis and condensation of tetraethyl orthosilicate (TEOS) in ethanol and water, catalyzed by ammonia. This produces monodisperse spherical particles with size tuned by adjusting reaction conditions. An alternative is the reverse microemulsion method developed in the 1990s. 6 MSNs are synthesized using evaporation-induced self-assembly developed in 1992. For example, surfactant molecules are added to form a template that is later extracted post-silica polymerization, leaving behind pores. 16, 97 MSNs can be functionalized on their external surface and within pores (Fig. 4b from Slowing et al.) , and hollow MSNs provide more volume for particulate transport. 169, 211 There are two main methods to alter surface chemistry: post-synthesis grafting or co-condensation of trialkyoxysilanes during nanoparticle synthesis. 160, 171 By altering surface chemistry to include peptides and antibodies, silica particles can target surface and intracellular markers. 96 
Silica Particles as MIRAs
Silica particles are often used as contrast agents to monitor stem cell therapy due to silica's tunable and biocompatible properties. Inclusion of contrast agents allows in vivo visualization of SCs with US, MRI, and PET. 72, 82, 88 MSNs were investigated for guiding cardiac SC therapy injection using US. MSN-loaded MSCs were delivered into the left ventricle of a mouse model and could monitor injected cells (Fig. 4c from Zhou et al.) . After one month, MSNs were degraded by intracellular pathways with little trace and no toxic effect, appealing qualities for clinical translation. 88 In conjunction with US, MRI has been used to monitor SCs in vivo by loading Gdlabeled SiNPs into MSCs. Particles could be imaged for up to 13 days, with the limiting factor being cell division dilution. 82 In another multimodal study, MSNs were functionalized with Cu, Gd, and a fluorophore, and implanted into MSCs for multimodal tracking using PET, MRI, and fluorescence. In vivo loading of the doped, MSN-labeled MSCs allowed tracking using PET and MRI simultaneously. 72 Silica particles' major strength is their ability to incorporate multiple contrast agents into a single element, which can provide numerous tracking options for clinicians in future applications.
Due to silica particles' surface functionalization, and specifically MSNs' porosity, silica is being investigated for drug and gene delivery. 53, 66, 134 MSNs undergo endocytosis in cells, including MSCs, with no adverse effect on differentiation, viability, and proliferation. 33 The large pore volume and surface area allows for nucleic acid, peptides, and polymers to be adsorbed, trapped, or bound. 176 This provides a multifunctional platform for controlled release and simultaneous sensing/imaging. MSNs showed the ability to transport membrane-impermeable proteins across cell membranes by trapping them within MSN (4) is injection of 500,000 labeled MSCs. 88 pores and releasing them intracellularly. 159 MSNs have been used as carriers for peptide mimetics to drive embryonic stem cell differentiation into functional motor neurons in vivo, and the differentiated SCs displayed long-term survival. 53 MSNs' extensive carrying abilities should continue to be investigated for optimizing TERM therapeutic delivery.
Silica particles have tunable porosity, mechanical properties, and bioactivity that provide helpful tools for use in scaffolds. In vitro studies demonstrated SiNPs promote differentiation of MSCs into osteoblasts. This translated well in vivo, where SiNPs increased bone mineral density. 15, 61 SiNPs/MSNs can interact especially well with the musculoskeletal system, considering their frequent incorporation into bone tissue engineering scaffolds. 52, 105, 144, 210 For instance, MSNs were embedded into a zein-hydroxypropyltrimethyl ammonium chloride chitosan (HACC) scaffold and implanted into a critical-sized radial bone defect in a rabbit model (Fig. 4d from Kempen et al.) . The scaffold provided structure and enhanced osteogenic differentiation to regenerate the missing bone segment. 210 These results demonstrate the future clinical relevance and promise of silica particles as orthopedic regenerative biomaterials. MSNs embedded in poly(caprolactone) have been used in laser tissue soldering, a tissue fusion method, due to their uptake and retention of ICG. ICG is a photodynamic agent that absorbs energy upon irradiation and releases energy as heat, which induces tissue fusion. The MSNs retain ICG in the scaffold before, during, and after irradiation, allowing for a constant reproducible temperature increase. An in vivo study demonstrated successful rabbit aortic artery tissue fusion with little thermal damage and intact endothelium because MSNs controlled photodynamic agent movement and minimized cytotoxic effects. 153 Future investigation combining photodynamic heating agents and scaffolds using silica particles may be crucial to developing an all-encompassing therapy.
Current Limitations
Silica-based nanoparticles are unable to act as effective MIRAs on their own due to inherently minimal contrast agent characteristics. Although they can be readily doped with other agents, incorporation requires a variety of chemical reactions, making it difficult to combine various particles for multi-modal imaging. Furthermore, adding various drugs or biomolecules for therapy can complicate development and limit which compounds bind to the silica. Combining separate contrast agents also raises concerns of leakage out of the system, causing reduced resolution and possible cytotoxicity. Another limitation is the large size of MSNs, which can limit cell uptake. Work is being done to reduce the size to sub-100nms and overcome this issue. Currently, silica nanoparticles are not FDA approved but are undergoing clinical trials for cancer therapy, which can be translated to tissue engineering in the future. 141 As research continues and these problems are solved, silica can begin to become a clinically viable MIRA.
Outlook
The future of silica particles as MIRAs lies in continuing to investigate capabilities with combinations of contrast and therapeutic agents. Silica particles are readily taken up by cells and well known functionalization techniques make them efficient gene and drug delivery agents. Silica has useful chemical properties for tissue scaffold development, and its bioactivity can simultaneously enhance SC differentiation. Their wellinvestigated chemical modifications have made SiNPs effective contrast agent carriers. While silica nanoparticles display some contrast in US, they are better suited as a carrier for MRI or PET contrast agents. Silica-based particles can provide novel therapy through therapeutic delivery and monitoring while acting as a scaffold base. Its most current clinically viable application lies in treating orthopedic disease. There have been some studies combining their therapeutic ability and imaging potential, but more work must be done to reach clinical relevance. Further investigation into silica particles' ability to monitor SC therapy with viability detection, scaffold engineering, and contrast agent cytotoxicity must be addressed prior to them becoming clinically relevant MIRAs.
PERFLUOROCARBON PARTICLES
PFCps have a long history in biomedical applications ranging from use as liquid ventilators to US contrast agents. More recently PFCp research has expanded to exploit their potential as multi-functional agents in a variety of TERM applications. PFCps are most studied as therapeutic carriers, capable of delivering drugs, genes, GFs, and oxygen to cells and tissues. PFCps are attractive therapeutic deliverers because combining them with PA or US allows for controlled release and in vivo monitoring of TERM therapy delivery. Other TERM applications of PFCps are targeted molecular imaging and delivery and scaffold monitoring.
PFCps are typically synthesized with emulsion techniques or microfluidic devices (Fig. 5a from Duncanson et al.). 45 The encapsulating PFCp shells are synthesized from polymers, lipids, proteins, or a com-bination of the aforementioned. 190 Their perfluorocarbon (PFC) core can be gaseous or liquid, depending on the chosen PFC compound. Gaseous forms of PFCps are called nanobubbles or microbubbles (MBs) based on their nano or micron diameter, while liquid forms are called nanodroplets or microdroplets, again based on size.
MBs have been extensively investigated as US contrast agents and were clinically approved as echocardiography contrast agents in 1992. 114 Their gaseous core offers a drastic acoustic impedance mismatch between the surrounding tissue and biological fluids, making them superb US contrast agents. 93 The fact that some PFCps are already clinically approved further emphasizes their potential as clinically used MIRAs.
Nanodroplet (ND) PFCps have recently gained attention as multimodal contrast agents capable of reaching places larger MBs cannot. 63, 151 Additionally, the use of ultrasound or laser irradiation can convert NDs into MBs for continued use as US contrast agents. US elicits phase change of droplets into bubbles through application of appropriate acoustic pressures, termed acoustic droplet vaporization (ADV). 154 Laser-induced phase change requires incorporating optical absorbers responsive to applied pulsed laser irradiation into NDs. Dyes (ICG, 1064 dye) and AuNRs were investigated as optical triggers for initiating phase transition from NDs to MBs. 63, 64, 190 Figure 5b from Hannah et al. shows ICG-loaded NDs and their PA/US contrast capabilities upon irradiation. 63 Droplet PFCps can also be monitored as in vivo 19 F MRI contrast agents due to their high fluorine concentrations. 76 Since fluorine is not present at high quantities in biological systems, the fluorine signal should only come from PFCps. This allows for high specificity of functional information which can then be combined with anatomical information gained through 1 H MRI. 57 
PFCps as MIRAs
PFCps have been widely investigated as therapeutic delivery agents. Charged species, such as genes, are normally loaded through electrostatic interactions with cationic PFCps. 4, 79 Cationic particles carry higher payloads of nucleic acids and better prevent premature degradation compared to neutral particles. 136 In the case of drug delivery, loading is primarily restricted to the PFCp shell area since drugs have limited solubility in the hydrophobic and lipophobic PFC. 174 Therefore, drugs are loaded by conjugating them to the outer layer, loading them within the shell, or within an oil encapsulating layer. 174 However, a recent study utilized microfluidic synthesis to create double emulsion PFCp droplets that encapsulated hydrophilic agents in their core (Fig. 5a from Duncanson et al.) . 45 Continuing to optimize PFCp synthesis and cargo capabilities could lead to more effective particles.
Gases are much simpler cargo because they are highly soluble within PFCs. Consequently, PFCps have been studied as oxygen carriers and blood substitutes for the past several decades. 14, 67, 150 Solubility of gases within PFCps is governed by Henry's law, which states that the gas's partial pressure will dictate solubility extent within PFCs. Gaseous delivery is beneficial for several TERM applications. A huge obstacle in SC-based angiogenic therapy is low cell survival upon implantation into ischemic tissue. 100 Increasing available oxygen to SCs until blood vessel ingrowth could improve current therapy outcomes. Groups have shown inclusion of oxygenated PFCps in SC-containing scaffolds increased cell viability and enhanced differentiation. 17, 43 PFCps can also deliver other gases such as the signaling molecule NO, which can mitigate vascular diseases like atherosclerosis. 165 Delivery of therapeutics is usually done in conjunction with US or PA/US. PA/US can be used to track particles in vivo and cause release of cargo at the desired site. This is especially true for drug and gene delivery. 132 Gaseous delivery usually relies on simple diffusion across the PFCp shell, but if higher release amounts are desired, PA/US techniques can be used. 165 As previously stated, irradiation of PFCps causes phase change from NDs into MBs. The forceful transition can result in stable cavitation. Similarly, application of US to MBs can cause stable or inertial cavitation. 178 Either way, cavitation exerts mechanical stresses on nearby cells and increases permeability of junctions or membranes allowing for increased delivery and uptake, an effect known as sonoporation. 132, 165 In one study, DNA containing MBs were able to achieve successful in vivo transfection of neural SCs. Prior to being implanted, neural SCs were loaded with MBs so that each cell had about 1-2 MBs adhered to their membrane or within endosomes. The MBs showed an increased lifetime of 5 days compared to circulation lifetimes of only hours for MBs in aqueous media. 172 US was used to induce cavitation of MBs and subsequent delivery of genes in a controlled manner with high specificity. 172 Whether PA or US is used to trigger cargo release, the contrast provided allows for monitoring the location of PFCps and control over therapeutic delivery, a valuable asset in TERM applications.
Several groups have studied the MB-US combination for increasing attachment of injected MSCs to the desired tissue. 94, 194, 207 Many TERM applications have a low percentage of SC retention and increasing retention would improve therapies. Localized cell delivery can occur by acoustic manipulation, in which cells coated with functionalized MBs are pushed to desired sites by US waves. 94 A more vigorous approach is to use US to induce cavitation of injected MBs, which causes changes in the microenvironment. 194, 207 This method was demonstrated in myocardium infarction models in vivo. The targeted cavitation of MBs resulted in increased expression of several cytokines, such as VEGF and vascular cell adhesion molecule 1 (VCAM-1), at the specified site, leading to higher MSC retention and ultimately a better angiogenic response. 207 Another MIRA application for PFCps is incorporating them into TERM scaffolds. Inclusion of droplet PFCps into scaffolds could control GF delivery. 119 For instance, fibrin hydrogels doped with microdroplets containing basic fibroblast growth factors (bFGF) could be acoustically activated to release bFGF. 48 Release of bFGFs was five times higher with US application. Also, changes in scaffold mechanical properties caused by the transition of droplets into bubbles could be regulated by varying US intensity. 48 These studies were conducted in vitro, but show the potential of controlling TERM agent release in vivo. This would provide future therapies with control and visualization of therapeutic release and allow treatment customization on a per patient basis.
Apart from inducing mechanical changes in scaffolds, inclusion of PFCps may allow for monitoring scaffold's mechanical properties. Young's moduli of hydrogels can be determined by measuring the displacement of bubbles embedded within the scaffolds. 47, 199 This technique has not been studied extensively, but presents an interesting possibility for non-destructive in vivo scaffold characterization. Changes in mechanical properties could convey information regarding scaffold degradation or tissue ingrowth.
Functionalizing PFCps with targeting ligands benefits therapy delivery and monitoring applications. In therapeutic delivery purposes, it allows for selective treatment of cell types and can be applied with previously addressed therapeutic agents. In monitoring, targeted PFCps can be coupled with either PA/US or 19 F MRI to convey functional and molecular information for assessing therapy progress. 178 For instance, studies that labeled MBs with VEGF receptors were able to track angiogenesis. 143 Although the original purpose was to assess angiogenesis in cancer models, the same technique could be used to monitor TERM revascularization therapies.
Another important parameter to monitor during TERM treatment course is inflammation. In vivo studies have shown that injected PFCps are preferentially taken up by circulating monocytes. The labeled cells will migrate towards areas of inflammation and can be detected by 19 F MRI (Fig. 5c from Jacoby et al.) 76 Monitoring the extent of inflammation will provide information on TERM treatment effective-ness. Furthermore, therapeutics to reduce inflammation could be loaded within PFCps and enhance their MIRA potential.
Current Limitations
In terms of clinical feasibility, PFCps have less hurdles to traverse than other agents since certain PFCps, namely MBs, have been FDA approved for several years. However, unlike other MIRAS, PFCps are limited by short lifetimes in aqueous solutions. This limits the window for therapeutic delivery, which is disadvantageous in long-term therapies. Fortunately, since many TERM applications involve cell encapsulation, PFCps can be incorporated into scaffolds and have an extended lifetime of several days. 172 Other concerns regarding PFCps include uncertainty of sonoporation effects. Despite being an active research area for the past 15 years, sonoporation's exact mechanisms remain relatively misunderstood. 49 More studies are needed to elucidate appropriate parameters for inducing cavitation to achieve effective therapeutic outcomes while maintaining cell function.
Outlook
PFCps demonstrate excellent therapeutic delivery and monitoring capabilities. The fact that several different PFCp contrast agents are FDA approved and have been in clinical use for several years has positive implications for other PFCp applications. PFCps used for targeted delivery are best used in conjunction with US/PA imaging techniques since release can be controlled via acoustic or light irradiation. Additionally, supplementing PA to US imaging allows for increased sensitivity and detection. Focus on prolonging the stability of PFCps and using them for longitudinal monitoring applications, such as cell tracking or scaffold assessment would benefit TERM applications. Future areas of interest regarding PFCp use as MIRAs include scaffold assessment in conjunction with shear imaging techniques and monitoring inflammation using 19 F MRI.
CONCLUSION
MIRAs' combined ability to enhance therapies and monitor different processes present unique opportunities for improving TERM treatments. The reviewed particles all show great potential as therapeutic and imaging agents. However, thus far therapy and imaging are still largely separated, and more research combining these applications is needed. While similar ideas have taken off in other biomedical fields, research related to combined TERM monitoring and therapy is still in its emerging stages. Continuing to study and develop MIRAs could prove critical to clinical translation of TERM therapies by elucidating current knowledge regarding TERM treatments and highlighting areas for improvement. In addition, MIRAs can allow clinicians to noninvasively evaluate treatments in vivo and modify therapy immediately. As noted throughout the review, each of the described particles has certain limitations and is often best suited for a specific type of application and imaging modality. Continuing to research MIRAs will give a clearer picture of which agent is best suited for particular TERM therapies. Researchers should also keep in mind hurdles for the described agents gaining FDA approval and strive to demonstrate particle safety through appropriate assays. Given the current state of research for TERM therapy and monitoring and the success of the closely related theranostic particles, there is great potential for MIRAs. 
